FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Cramer: What Monday’s Housing Number Really Means
- Cramer: Buy These Banks, If...
- Time to Buy Treasurys?
- Lightning Round: Las Vegas Sands, ADC Telecom, Satyam Computer and More
- Lightning Round OT: Knight Capital, Ebix and More
- Is Lear, Back From Bankruptcy, a Buy?
- Sanofi-Aventis Falling Off a Patent Cliff?
- Cramer: Your Thanksgiving Week Game Plan
- Cramer: Next Week Should Define Rest of ‘09
- Mad Money: Mad Mail: Buy RIM or Apple?
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Text Size 
The health care industry has been shaking in its scrubs ever since President Obama decided on a sweeping overhaul. Wall Street, apparently just as scared, has responded by selling the sector’s stocks. But while everyone has been wondering how big a hit these companies would take, Cramer has said that one group among them could be spared – the cost cutters. That’s why he’s bullish on MedcoHealth Solutions.
This pharmacy benefit manager uses its bargaining power to get its customers lower drug prices and then pockets the difference. The big money is made when brand-name drugs go off patent. For every $100 million worth of branded drugs that go generic, Medco’s [MHS
Loading...
()
] clients save $45 million and the company earns $9 million. That makes for some exciting prospects between 2008 and 2015, which should see $104.7 billion worth of drugs lose patent protection. The potential payout for Medco? $9.4 billion.
Medco also cuts costs with its Therapeutic Resource Centers, which keep doctors and patients in line with accepted treatment protocols, specifically for chronic and complex diseases. Considering that these diseases are responsible for 96% of drug spending and 75% of all health-care costs, billions of dollars are lost when those protocols are ignored. Thanks to Medco, some of that waste is being reduced.
From an investor’s standpoint, Medco has another thing going for it: growth. Cramer put it on par with Google [GOOG
Loading...
()
] and Apple [AAPL
Loading...
()
]. The company’s long-term growth rate is 18.5%, but the stock is trading at just 14 times 2010 earnings. That’s incredibly cheap, and it’s not a stretch to assume that money managers would pay 18.5 times those earnings – one times the growth rate – for MHS. Such a move would push this $46 stock to $56 for a nice $10 gain.
But will Medco truly survive Obama’s reforms? Cramer invited Medco Chairman and CEO David Snow onto Mad Money to find out. Watch the video for that answer, as well as Snow’s take on the root-cause problems is health care, besting Wal-Mart and a possible CVS Caremark breakup.
Call Cramer: 1-800-743-CNBC
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes